UBS Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
Other funds holding AKBA
UBS Group's AKBA Position: Q3 2026 in Review
UBS Group increased its Akebia Therapeutics (AKBA) stake by 6.3% in Q3 2026, buying an estimated $92.8K and bringing the position to 1,461,231 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5383.
UBS Group first reported a position in AKBA in Q2 2014 and has held it in 50 quarters since. The position peaked at $10M in Q3 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.
- UBS Group held 1,461,231 shares of Akebia Therapeutics worth $1.34M as of Q3 2026.
- UBS Group bought 86,281 Akebia Therapeutics shares in Q3 2026, an estimated $92.8K.
- Akebia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #5383 holding.
- UBS Group first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 50 quarters since.
- UBS Group's Akebia Therapeutics position peaked at $10M in Q3 2025.
- 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.